On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant. On September ...
Teclistamab-cqyv significantly improves progression-free and overall survival in relapsed/refractory multiple myeloma, especially in patients refractory to anti-CD38 therapy and lenalidomide. The ...
The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...
In Europe, the SC formulation of daratumumab, another anti-CD38 antibody, recently received a label update that allowed ...
Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and ...
An investigational anti-CD38 monoclonal antibody (CM313) rapidly increased platelets in immune thrombocytopenia (ITP) patients to levels sufficient for preventing bleeding, a small single-arm Chinese ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, ...
The University of Michigan John Varga Lab, in collaboration with the Mayo Clinic and Northwestern researchers, published an article last year suggesting that a heavy-chain monoclonal antibody, Ab68, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results